LRP1B and posterior cortical atrophy: Other biomarkers that have been identified as potentially predictive of the response to pembrolizumab in patients with PCa include the presence of mutations in the low-density lipoprotein receptor-related protein 1b gene (LRP1b) (75% response rate in LRP1b-mutated tumors vs. 14% in tumors without LRP1b mutations in a retrospectively reviewed cohort of 48 men who received ≥1 cycle of pembrolizumab for mCRPC, with high correlation between LRP1b mutations and TMB-high) [120].